FP 1096

Drug Profile

FP 1096

Alternative Names: Endometriosis treatment - FemmePharma; FP1096; PARDEL™ endometriosis treatment - FemmePharma

Latest Information Update: 23 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FemmePharma; KV Pharmaceutical Company
  • Developer FemmePharma
  • Class Hormones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Endometriosis

Most Recent Events

  • 12 Jun 2014 Discontinued - Phase-III for Endometriosis in USA (Vaginal)
  • 29 May 2014 KV Pharmaceutical is now called Lumara Health
  • 08 Sep 2009 No development reported - Phase-III for Endometriosis in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top